[vc_row][vc_column][vc_column_text margin_bottom=”10″]Baltimore, MD (June 8, 2012)

Today, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) announced the launch of its operations, dedicated to improving treatment options for individuals with plexiform neurofibromas (pNFs). NTAP is a non-profit organization formed to accelerate the development of effective treatments that will stop, reverse, and ultimately cure pNFs, the most common tumor seen in patients with neurofibromatosis type 1 (NF1). By engaging directly with patients, basic researchers, clinical investigators, regulatory bodies and commercial partners, NTAP will identify where resources are most urgently needed to create novel treatments for this disease. The organization will then strategically fund programs around the world to ensure patients can benefit from research advances as quickly as possible.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][blockquote style=”style5″ align=”center”]We were delighted to host this group of exceptional participants whose input has been invaluable in helping to prioritize the initiatives we will support in our grant programs,” said Jaishri Blakeley, Director of NTAP. “By bringing together the perspectives of stakeholders from every stage of the drug development process and clinical management of the disease, we were able to identify crucial gaps in “knowledge and tools that limit the development of therapeutics for pNF. Our next steps will be to direct resources to those gaps and remove obstacles so innovative discoveries can be efficiently translated into improved outcomes for pNF patients.”[/blockquote][vc_column_text margin_bottom=”20″]NTAP was founded through a philanthropic gift to the Johns Hopkins University (JHU) School of Medicine and does not seek donations from the public. For further information about NTAP and its programs, please see n-tap.org